G OWING PAIN
In Europe and the United States, there are 500-1,000 new cases of CLI per 1 million people each year 3 .
The risk of developing CLI is increased for patients with certain risk factors, including hypertension, diabetes and smoking 1 .
CU ENT T EATMENTS
The gold standard in treatment for CLI is surgery to unblock or widen the obstructed blood vessel, or to bypass it through another vessel. 
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RESCUE THROUGH REGENERATION
Up to 30% of people 4 with CLI are unable to undergo surgical treatments for the condition because their arteries are too calci ed or they have another condition that prevents it.
As an alternative, researchers are investigating whether new blood vessels can be encouraged to grow, thereby restoring the supply of blood to the a ected limb. Gene and cell-based therapies are the main regenerative-medicine approaches being pursued.
GENE THE APY
A modi ed virus or other vector is used to insert genes into the cells that line the inner wall of the blood vessel. These genes encode proteins, such as vascular endothelial growth factor (VEGF), that promote the growth of new blood vessels.
So far, gene therapies have been shown to improve wound healing in patients, but do not considerably prolong the length of time between diagnosis with CLI and limb amputation 5 . Targeting the correct cells is crucial because promoting blood-vessel formation in healthy tissues might increase the risk of tumours.
CELL THE APY
Cells from the patient are used to supply substances that promote blood-vessel formation and boost the growth of new arteries to the a ected limb. Cell therapy seems to provide a more sustained and targeted release of such substances than gene therapy.
Small phase I and phase II clinical trials have shown that cell-based therapies are safe and improve wound healing, but the trials were not large enough to detect any improvements in delaying amputation 4 .
Blood-vessel growth allows blood to bypass the blockage.
Blood vessels grow into the a ected limb, improving the blood supply.
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NEXT STEPS
E orts to optimize cell-based therapies for CLI are under way. One approach is to increase the proportion of a type of mononuclear cell called endothelial progenitor cells (EPCs), which have a role in blood-vessel regeneration, in the injected cells. This is achieved by selecting cells that express the protein CD34 on their surface. A small 2009 trial 6 showed that people who received such CD34-expressing cells showed improvements in pain scores and in the distance that they could walk. A larger trial is being planned in Japan for later this year to test whether the therapy can delay or prevent the need for amputation. CRITICAL LIMB ISCHAEMIA OUTLINE
